https://doi.org/10.5812/ijcm-136310

Incidence Trend of Brain Tumors in Iran: A Systematic Review and Meta-analysis

authors:

avatar Sohrab Sadeghi 1 , avatar Hassan Reza Mohammadi 1 , *

Department of Neurosurgery, Imam Hossein Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
International Journal of Cancer Management: Vol.16, issue 1; e136310
published online: June 11, 2023
article type: Systematic Review
received: March 13, 2023
revised: April 5, 2023
accepted: April 29, 2023

How To Cite Sadeghi S, Mohammadi H R. Incidence Trend of Brain Tumors in Iran: A Systematic Review and Meta-analysis. Int J Cancer Manag. 2023;16(1):e136310. https://doi.org/10.5812/ijcm-136310.

Abstract

Context:

Primary brain tumor (PBT) causes poor prognosis and significant complications, which include movement problems such as balance disorders, failed return to work, and daily life activities.

Objectives:

The aim of the present study is to estimate the prevalence of PBT in Iran, using a meta-analysis method.

Methods:

This meta-analysis study was conducted in Iran in 2023 and articles published until the beginning of 2023 were included in the study, using the English keywords of brain cancer, brain tumor, tumor prevalence, prevalence, cancer, nervous system cancer, and their Persian equivalents. Data analysis was carried out, using CMA software.

Results:

After the initial search, 890 articles on BT were found, and 21 eligible articles were included in the meta-analysis. Also, the prevalence of brain cancer is 4% (95%CI: 3.3 - 4.8) in men and 2.9% (95%CI: 2.3 - 3.6) in women.

Conclusions:

According to the result, the BT incidence rate is 4% for males and 2.9% for females. Therefore, it is necessary to take necessary preventive measures in this regard.

1. Context

Spinal cord and brain diseases are among the sensitive and important diseases related to the central and peripheral nervous system (1-3). These diseases can have destructive health-related effects, including the patient's quality of life (4-6). Primary brain tumor (PBT) includes benign and malignant tumors, whose origin is related to the brain parenchyma and its surrounding structures, which occur at all ages, but its prevalence is higher in adults (7, 8). Like other types of tumors, the PBT etiologies are also unknown, but factors such as environment, genetics, ionizing radiation, and some hereditary disorders have been effective in causing it (7, 9).

Due to its different prevalence, nature of the treatment, and survival rates, PBT is of special importance and, thus, special prevention and treatment measures should be taken. PBT causes poor prognosis and significant complications, which include movement problems such as balance disorders, failed return to work, and daily life activities (10-12). Primary brain tumor can be primary or metastatic and appear in different parts of the brain. According to the anatomical location of involvement in BT, the clinical symptoms of these types of tumors are different from other types of cancer, but complications such as pain, vision impairment, weight loss, dry mouth, dysphagia, fatigue, and sleep disorders may occur in all these patients (13, 14).

The most common types of PBT in adults include glioblastoma (GBM), ependymoma, miscellaneous, astrocytoma, and medulloblastoma/PNET. Glioblastoma is one of the most aggressive and common PBTs, which proliferates widely in the healthy brain and poses a challenge to the patient's survival due to subsequent chemical changes in the brain; that is, the survival rate may survive 3 and 12 months (15-17). Brain metastases (BMs) are one of the most common intracerebral malignancies in adults, and surgery or radiation therapy are chosen as the main treatment for these patients. Brain metastas symptoms are caused by edema, and this type of edema can expand several times more than the volume of tumors and interfere with the patient's treatment due to neurological dysfunction (18-20).

Cancer prevention is very important and epidemiological studies and meta-analyses can provide accurate information to researchers so that they know the disease severity (21-24).

2. Objectives

Estimating the disease prevalence can be regarded as an important step in the planning of preventive and therapeutic measures for a disease; for this reason, the aim of this study is to estimate the prevalence of PBT in Iran, using a meta-analysis method.

3. Methods

This meta-analysis study was conducted in Iran and articles published until the beginning of 2023 (January) were included in the study, using the English keywords of brain cancer, brain tumor, tumor prevalence, prevalence, PBT, cancer, nervous system cancer, and their Persian equivalents. Articles that investigated the age-standardized incidence rates (ASRs) of cancer in adults were included in the study.

The search was carried out in the domestic databases of Iran such as the international databases of Cochrane, Embase, ScienceDirect, Scopus, PubMed, and Web of Science.

If the information requested in the articles is complete (Table 1) and inclusion criteria are met, including the incidence rate report ASRs of BT in each of the cities of Iran, and the complete information are available, the eligible article entered the meta-analysis phase. Data analysis was carried out, using CMA 3 software.

Table 1.

Specifications of the Articles Included in the Systematic Review

AuthorsCityYearsSample SizeASRs
MaleFemaleMaleFemale
1Araghi et al. (25)Goleston2004 - 20134803706.95.3
2Roshandel et al. (26)Registry201460469516286.664.88
3Asgarian et al. (27)Kashan20047384762.371.64
20057614962.461.67
20068636022.772.04
20078956292.842.17
200813008944.163.09
4Salimi et al. (28)Cancer registry2020969568525.563.93
5Sadjadi et al. (29)Ardabil2003207213094.43.1
6Fateh and Emamian (30)Cancer registry2013123410063.652.79
7Babaei et al. (31)Semnan200593679676.26
8Mohagheghi et al. (32)Cancer registry2009174071515464.5
9Somi et al. (33)East Azerbaijan2009254611759.398.06
10Somi et al. (34)East Azerbaijan2008279820854.985.48
11Vafajo Diantai et al. (35)Ghom2014196114381.881.5
12Mousavi et al. (36)-2003 - 200421620168491.881.26
2004 - 200526743204732.371.64
2005 - 200631360244952.511.71
13Mehrabani et al. (37)Fars2008149516202.081.46
14Amori et al. (38)Iran2016168 783132 2722.711.64
15Tolou-Ghamari (39)Isfahan20206204238.23.8
6204236.33.8
6204237.34.6
6204236.45
16Almasi et al. (40)Cancer registry201644,838399914.63.8
17Tolou-Ghamari (41)Isfahan202015,82714638--
18Norouzirad et al. (42)Dezful201712709323.091.10
19Sadjadi et al. (43)Kerman2007326426202.92.3
20Masoompour et al. (44)Registry20114549381032.2

Abbreviation: ASRs, age-standardized incidence rates.

4. Results and Discussion

After the initial search, 890 articles on BT were found and 21 eligible articles were included in the study (Figure 1).

Flowcharts for systematic review
Flowcharts for systematic review
Figure 1.

Flowcharts for systematic review

Results showed that the prevalence of BT is 4% (95%CI: 3.3 - 4.8) in men and 2.9% (95%CI: 2.3 - 3.6) in women (Figures 2 and 3). Also, in Figures 4 and 5, the state of bias publication is shown. On the other hand, according to Figures 5, 6, 7, 8 and 9, there was no relationship between the year of conducting the studies and the sample size with the status of ASRs.

Prevalence of BT in Iranian men
Prevalence of BT in Iranian men
Figure 2.

Prevalence of BT in Iranian men

Prevalence of BT in females in Iran
Prevalence of BT in females in Iran
Figure 3.

Prevalence of BT in females in Iran

Publication bias for BT in females in Iran
Publication bias for BT in females in Iran
Figure 4.

Publication bias for BT in females in Iran

Meta-regression according to the number of patients for Iranian females (P = 0.38, Z = -0.87)
Meta-regression according to the number of patients for Iranian females (P = 0.38, Z = -0.87)
Figure 5.

Meta-regression according to the number of patients for Iranian females (P = 0.38, Z = -0.87)

Meta-regression according to the number of patients for Iranian men (P = 0.45, Z = -0.74)
Meta-regression according to the number of patients for Iranian men (P = 0.45, Z = -0.74)
Figure 6.

Meta-regression according to the number of patients for Iranian men (P = 0.45, Z = -0.74)

Meta-regression according to the time of publishing article for Iranian men (P = 0.77, Z = 0.29)
Meta-regression according to the time of publishing article for Iranian men (P = 0.77, Z = 0.29)
Figure 7.

Meta-regression according to the time of publishing article for Iranian men (P = 0.77, Z = 0.29)

Publication bias for BT in females in Iran
Publication bias for BT in females in Iran
Figure 8.

Publication bias for BT in females in Iran

Meta-regression according to the time of publishing for Iranian females (P = 0.77, Z = 0.29)
Meta-regression according to the time of publishing for Iranian females (P = 0.77, Z = 0.29)
Figure 9.

Meta-regression according to the time of publishing for Iranian females (P = 0.77, Z = 0.29)

The results also showed that the prevalence of brain cancer is 4% (95%CI: 3.3 - 4.8) in men and 2.9% (95%CI: 2.3 - 3.6) in women. The cancer prevalence was analyzed in meta-analyses in Iran and other studies. In this regard, in a review of 24 articles, Kazeminia et al. investigated the prevalence of breast cancer in 39 596 patients from 1965 to 2019 and it was observed that the overall ASR of breast cancer was 23.6% (45). In a meta-analysis of 17 articles published until 2017, Hassanipour et al. reported that the ASR rate for kidney cancer in men and women was 1.94 and 1.36, respectively (46). In another meta-analysis of 21 articles, Hassanipour et al. found that the ASR rate for prostate cancer was 9.11% (47). In another meta-analysis of 28 articles with a sample size of 100 869, Salari et al. reported that the ASR for thyroid cancer was 3.5% (48). According to the results of the aforementioned studies, in Iran, the cancer incidence in each organ of the human body has been variable. Such differences can be attributed to the role of background factors such as age, gender, environment, and pathogenic risk factors that may have influenced the prevalence of different types of cancer (49-51).

Sadeghi et al. found that the BT prevalence in Iranian people under 18 years of age was 2%, which is lower than the results of the present study (52). This discrepancy may be due to the difference in the number of reviewed articles (21 articles in the present study and 8 articles in Sadeghi et al.'s study), diversity in the sample size, and the difference in the age group under study (all age groups in the current study, but only people under 18 years of age in Sadeghi et al.'s study), each of which affects the BT incidence. On the other hand, the BT incidence was investigated between 2000 and 2009 in Iran; in a study by Jazayeri et al., it was observed that the incidence of malignant PBTs was 3.3% of all tumors (per 100 000) compared to other tumors, which was 3.9 in men and 2.8 in women (53). All the data reviewed in Jazayeri et al.'s study were related to the annual national reports of cancer registration (n = 11 cases), while only the data available in the published articles (original or national reports of cancer registration in the form of registry) were included in the present study.

In a meta-analysis of 36 articles with a sample size of 37 697, Nakasu et al. reported that the incidence of meningiomas and gliomas was 0.52% (54). Also, BT was reported in 4 400 cancer patients out of 267 450 patients (incidence rate = 2%) in a study by McKinney (55), which is consistent with the results of the present study that suggest the significant incidence of BT in cancer patients. In the context of high prevalence in men compared to women, in the study of Jiang et al., the prevalence in men and women is equal (56), Also, in Porter's study, the prevalence in women was higher than in men, which is not consistent with this study (57).

5. Conclusions

According to the result, the BT incidence rate is 4% for males and 2.9% for females. Therefore, it is necessary to take necessary preventive measures in this regard.

References

  • 1.

    Hatefi M, Komlakh K. The effect of Atorvastatin on chronic subdural hematoma status: A systematic review of drug therapy. Eurasian Chem Commun. 2022;4(11):1130-7. https://doi.org/10.22034/ecc.2022.345173.1483.

  • 2.

    Komlakh K, Karbasfrushan A. The effect of Pregabalin on the pain status of patients with disc and spinal surgeries: A systematic review of drug therapy. Eurasian Chem Commun. 2022;4(11):1147-55. https://doi.org/10.22034/ecc.2022.348692.1491.

  • 3.

    Karacabey S, Sanrı E. Optic Nerve Sheath Diameter Affected by Cervical Collar Placement in Minor Head Trauma Patients. Iran Red Crescent Med J. 2022;24(10):e1530. https://doi.org/10.32592/ircmj.2022.24.10.1530.

  • 4.

    Mohammadi H, Sadeghi S, Zandi S. Central Nervous System Aspergilloma in an Immunocompetent Patient: A Case Report. Iran J Public Health. 2015;44(6):869-72. [PubMed ID: 26258101]. [PubMed Central ID: PMC4524313].

  • 5.

    Azimi P, Ghandehari HS, Sadeghi S, Azhari S, Aghaei HN, Mohmmadi HR, et al. Severity of symptoms, physical functioning and satisfaction in patients with lumbar spinal stenosis: a validation study of the Iranian version of the Swiss Spinal Stenosis Score. J Neurosurg Sci. 2014;58(3):177-82.

  • 6.

    Taheri Z, Babaee T, Hajiaghaei B, Mohammadi HR. Cranial remolding orthosis for postoperative management of bilateral lambdoid and sagittal synostosis: A case report. Prosthet Orthot Int. 2021;45(3):235-9. [PubMed ID: 33856156]. https://doi.org/10.1097/PXR.0000000000000005.

  • 7.

    Katchy KC, Alexander S, Al-Nashmi NM, Al-Ramadan A. Epidemiology of primary brain tumors in childhood and adolescence in Kuwait. Springerplus. 2013;2(1):58. [PubMed ID: 23519270]. [PubMed Central ID: PMC3601263]. https://doi.org/10.1186/2193-1801-2-58.

  • 8.

    Haghshenas MR, Saffarian A, Khademolhosseini A, Dehghanian A, Ghaderi A, Sotoodeh Jahromi A. Simultaneous Increase in Serum Levels of IL-37 and IL-18 Binding Protein In Low-Grade and High-Grade Brain Tumors. Asian Pac J Cancer Prev. 2022;23(8):2851-6. [PubMed ID: 36037143]. [PubMed Central ID: PMC9741882]. https://doi.org/10.31557/APJCP.2022.23.8.2851.

  • 9.

    Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109(1):93-108. [PubMed ID: 15685439]. https://doi.org/10.1007/s00401-005-0991-y.

  • 10.

    Rogers JL, De La Cruz Minyety J, Vera E, Acquaye AA, Payen SS, Weinberg JS, et al. Assessing mobility in primary brain tumor patients: A descriptive feasibility study using two established mobility tests. Neurooncol Pract. 2022;9(3):219-28. [PubMed ID: 35601968]. [PubMed Central ID: PMC9113321]. https://doi.org/10.1093/nop/npac013.

  • 11.

    Sunrat C, Kwanthongdee J, Uppakara K, Chabang N, Munyoo B, Tuchinda P, et al. Phyllanthus taxodiifolius Beille Disrupted N-cadherin, Vimentin, Paxillin and Actin Stress Fibers in Glioblastoma. Asian Pac J Cancer Prev. 2022;23(7):2379-86. [PubMed ID: 35901345]. [PubMed Central ID: PMC9727360]. https://doi.org/10.31557/APJCP.2022.23.7.2379.

  • 12.

    Alahverdi A, Arefian E, Soleimani M, Ai J, Yousefi-Ahmadipour A, Babaei A, et al. Involvement of EGFR, ERK-1,2 and AKT-1,2 Activity on Human Glioma Cell Growth. Asian Pac J Cancer Prev. 2020;21(12):3469-75. [PubMed ID: 33369441]. [PubMed Central ID: PMC8046313]. https://doi.org/10.31557/APJCP.2020.21.12.3469.

  • 13.

    Molassiotis A, Rogers M. Symptom experience and regaining normality in the first year following a diagnosis of head and neck cancer: a qualitative longitudinal study. Palliat Support Care. 2012;10(3):197-204. [PubMed ID: 22613011]. https://doi.org/10.1017/S147895151200020X.

  • 14.

    Hanna EY, Mendoza TR, Rosenthal DI, Gunn GB, Sehra P, Yucel E, et al. The symptom burden of treatment-naive patients with head and neck cancer. Cancer. 2015;121(5):766-73. [PubMed ID: 25369213]. [PubMed Central ID: PMC4339345]. https://doi.org/10.1002/cncr.29097.

  • 15.

    Bastiancich C, Bozzato E, Henley I, Newland B. Does local drug delivery still hold therapeutic promise for brain cancer? A systematic review. J Control Release. 2021;337:296-305. [PubMed ID: 34298055]. https://doi.org/10.1016/j.jconrel.2021.07.031.

  • 16.

    Thammaroj J, Wongwichit N, Boonrod A. Evaluation of Perienhancing Area in Differentiation between Glioblastoma and Solitary Brain Metastasis. Asian Pac J Cancer Prev. 2020;21(9):2525-30. [PubMed ID: 32986348]. [PubMed Central ID: PMC7779443]. https://doi.org/10.31557/APJCP.2020.21.9.2525.

  • 17.

    Fadl-Elmula I, Giha R, Deaf SAH, El Hassan LA, Hassan AM, Arbab MAR. Rare Suprasellar Chordoid Meningioma with INI1 Gene Mutation. Sudan Journal of Medical Sciences. 2017;12(3):198-206. https://doi.org/10.18502/sjms.v12i3.1001.

  • 18.

    Flanigan JC, Jilaveanu LB, Chiang VL, Kluger HM. Advances in therapy for melanoma brain metastases. Clin Dermatol. 2013;31(3):264-81. [PubMed ID: 23608446]. https://doi.org/10.1016/j.clindermatol.2012.08.008.

  • 19.

    Kerschbaumer J, Bauer M, Popovscaia M, Grams AE, Thome C, Freyschlag CF. Correlation of Tumor and Peritumoral Edema Volumes with Survival in Patients with Cerebral Metastases. Anticancer Res. 2017;37(2):871-5. [PubMed ID: 28179345]. https://doi.org/10.21873/anticanres.11392.

  • 20.

    Tran TT, Mahajan A, Chiang VL, Goldberg SB, Nguyen DX, Jilaveanu LB, et al. Perilesional edema in brain metastases: potential causes and implications for treatment with immune therapy. J Immunother Cancer. 2019;7(1):200. [PubMed ID: 31362777]. [PubMed Central ID: PMC6668163]. https://doi.org/10.1186/s40425-019-0684-z.

  • 21.

    Ghalavand M, Parandin F, Lutfi E, Lotfi H, Shourideh Yazdi N, Dorostkar R, et al. Oncolytic Bacterial and Viral Therapies as Cancer Prevention and Treatment Options: A Comprehensive Review. Iran Red Crescent Med J. 2022;24(8):e1990. https://doi.org/10.32592/ircmj.2022.24.8.1990.

  • 22.

    Langarizadeh M, Sayadi M. Machine Learning Techniques for Diagnosis of Lower Gastrointestinal Cancer: A Systematic Review. Iran Red Crescent Med J. 2021;23(7):e436. https://doi.org/10.32592/ircmj.2021.23.7.436.

  • 23.

    Wang W, Cai L, Xiao B, Huang R. Risk of Hypertension Associated with Antivascular Endothelial Growth Factor Monoclonal Antibodies: A Meta-Analysis From 51088 Patients with Cancer. Iran Red Crescent Med J. 2020;22(7):e100785. https://doi.org/10.5812/ircmj.100785.

  • 24.

    Esmail Nasab N, Moradi G, Zareie M, Ghaderi E, Gheytasi B. [Survey of epidemilogic status and incidence rates of cancers in the patients above 15 years old in Kurdistan province]. Sci J Kurdistan Univ Med Sci. 2007;11(4):18-25. Persian.

  • 25.

    Araghi M, Roshandel G, Hasanpour-Heidari S, Fazel A, Sedaghat SM, Pourkhani A, et al. Incidence of Malignant Brain and Central Nervous System Tumors in Golestan, Iran, 2004-2013. Arch Iran Med. 2020;23(1):1-6. [PubMed ID: 31910628].

  • 26.

    Roshandel G, Ghanbari-Motlagh A, Partovipour E, Salavati F, Hasanpour-Heidari S, Mohammadi G, et al. Cancer incidence in Iran in 2014: Results of the Iranian National Population-based Cancer Registry. Cancer Epidemiol. 2019;61:50-8. [PubMed ID: 31132560]. https://doi.org/10.1016/j.canep.2019.05.009.

  • 27.

    Asgarian FS, Moraveji A, Mahdian M, Akbari H. Epidemiological Features and the Incidence Trend of Brain Cancers in Iran (2004-2008). Int J Prev Med. 2022;13:149. [PubMed ID: 36911008]. [PubMed Central ID: PMC9999093]. https://doi.org/10.4103/ijpvm.IJPVM_629_20.

  • 28.

    Salimi A, Zali A, Seddighi AS, Seddighi A, Meshkat S, Hosseini M, et al. Descriptive Epidemiology of Brain and Central Nervous System Tumours: Results from Iran National Cancer Registry, 2010-2014. J Cancer Epidemiol. 2020;2020:3534641. [PubMed ID: 33014059]. [PubMed Central ID: PMC7520005]. https://doi.org/10.1155/2020/3534641.

  • 29.

    Sadjadi A, Malekzadeh R, Derakhshan MH, Sepehr A, Nouraie M, Sotoudeh M, et al. Cancer occurrence in Ardabil: results of a population-based cancer registry from Iran. Int J Cancer. 2003;107(1):113-8. [PubMed ID: 12925965]. https://doi.org/10.1002/ijc.11359.

  • 30.

    Fateh M, Emamian MH. Cancer incidence and trend analysis in Shahroud, Iran, 2000 - 2010. Iran J Cancer Prev. 2013;6(2):85-94. [PubMed ID: 25250116]. [PubMed Central ID: PMC4142911].

  • 31.

    Babaei M, Mousavi S, Malek M, Tosi G, Masoumeh Z, Danaei N, et al. Cancer occurrence in Semnan Province, Iran: results of a population-based cancer registry. Asian Pac J Cancer Prev. 2005;6(2):159-64. [PubMed ID: 16101326].

  • 32.

    Mohagheghi MA, Mosavi-Jarrahi A, Malekzadeh R, Parkin M. Cancer incidence in Tehran metropolis: the first report from the Tehran Population-based Cancer Registry, 1998-2001. Arch Iran Med. 2009;12(1):15-23. [PubMed ID: 19111024].

  • 33.

    Somi MH, Mousavi SM, Rezaeifar P, Naghashi SH. Cancer Incidence among the Elderly Population in the Northwest of Iran: A Population Based Study. Iran J Cancer Prev. 2009;2(3):117-26.

  • 34.

    Somi MH, Farhang S, Mirinezhad SK, Naghashi S, Seif-Farshad M, Golzari M. Cancer in East Azerbaijan, Iran: results of a population-based cancer registry. Asian Pac J Cancer Prev. 2008;9(2):327-30. [PubMed ID: 18712985].

  • 35.

    Vafajo Diantai Z, Abedini Z, Ahmari Tehran H, Mohamadgholizade L. [Epidemiology of cancer in Qom, Iran 2008-2011]. Payesh. 2014;13(2):155-63. Persian.

  • 36.

    Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Ann Oncol. 2009;20(3):556-63. [PubMed ID: 19073863]. https://doi.org/10.1093/annonc/mdn642.

  • 37.

    Mehrabani D, Tabei SZ, Heydari ST, Shamsina SJ, Shokrpour N, Amini M, et al. Cancer Occurrence in Fars Province, Southern Iran. Iran Red Crescent Med J. 2008;10(4):314-22.

  • 38.

    Amori N, Aghajani M, Asgarian FS, Jazayeri M. Epidemiology and trend of common cancers in Iran (2004-2008). Eur J Cancer Care (Engl). 2017;26(5):e12449. [PubMed ID: 26811194]. https://doi.org/10.1111/ecc.12449.

  • 39.

    Tolou-Ghamari Z. Preliminary study of central nervous system tumors' prevalence and incidence in Isfahan Province Iran. J Egypt Natl Canc Inst. 2020;32(1):14. [PubMed ID: 32372298]. https://doi.org/10.1186/s43046-020-00022-8.

  • 40.

    Almasi Z, Mohammadian-Hafshejani A, Salehiniya H. Incidence, mortality, and epidemiological aspects of cancers in Iran; differences with the world data. J BUON. 2016;21(4):994-1004. [PubMed ID: 27685925].

  • 41.

    Tolou-Ghamari Z. Prevalence and demographic characteristics of cancers. Clin Cancer Investig J. 2020;9(1):13-8.

  • 42.

    Norouzirad R, Khazaei Z, Mousavi M, Adineh HA, Hoghooghi M, Khabazkhoob M, et al. Epidemiology of common cancers in Dezful county, southwest of Iran. Immunopathol Persa. 2018;4(1):e10. https://doi.org/10.15171/ipp.2018.10.

  • 43.

    Sadjadi A, Zahedi MJ, Darvish Moghadam S, Nouraie M, Alimohammadian M, Ghorbani A, et al. The First Population-Based Cancer Survey in Kerman Province of Iran. Iran J Public Health. 2007;36(4):26-34.

  • 44.

    Masoompour SM, Yarmohammadi H, Rezaianzadeh A, Lankarani KB. Cancer incidence in southern Iran, 1998-2002: results of population-based cancer registry. Cancer Epidemiol. 2011;35(5):e42-7. [PubMed ID: 21840285]. https://doi.org/10.1016/j.canep.2011.05.018.

  • 45.

    Kazeminia M, Salari N, Hosseinian-Far A, Akbari H, Bazrafshan M, Mohammadi M. The Prevalence of Breast Cancer in Iranian Women: A Systematic Review and Meta-Analysis. Indian J Gynecol Oncolog. 2022;20(1):14. https://doi.org/10.1007/s40944-022-00613-4.

  • 46.

    Hassanipour S, Namvar G, Fathalipour M, Salehiniya H. The incidence of kidney cancer in Iran: a systematic review and meta-analysis. Biomedicine (Taipei). 2018;8(2):9. [PubMed ID: 29806587]. [PubMed Central ID: PMC5992926]. https://doi.org/10.1051/bmdcn/2018080209.

  • 47.

    Hassanipour S, Fathalipour M, Salehiniya H. The incidence of prostate cancer in Iran: a systematic review and meta-analysis. Prostate Int. 2018;6(2):41-5. [PubMed ID: 29922630]. [PubMed Central ID: PMC6004615]. https://doi.org/10.1016/j.prnil.2017.11.003.

  • 48.

    Salari N, Kazeminia M, Mohammadi M. The Prevalence of Thyroid Cancer in Iran: a Systematic Review and Meta-analysis. Indian J Surg Oncol. 2022;13(1):225-34. [PubMed ID: 35462666]. [PubMed Central ID: PMC8986894]. https://doi.org/10.1007/s13193-021-01465-8.

  • 49.

    Marjani HA, Biramijamal F, Hossein-Nezhad A, Islami F, Pourshmas A, Semnani S. Prevalence of esophageal cancer risk factors among Turkmen and non-Turkmen ethnic groups in a high incidence area in Iran. Arch Iran Med. 2010;13(2):111-5. [PubMed ID: 20187664].

  • 50.

    Pressoir M, Desne S, Berchery D, Rossignol G, Poiree B, Meslier M, et al. Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres. Br J Cancer. 2010;102(6):966-71. [PubMed ID: 20160725]. [PubMed Central ID: PMC2844030]. https://doi.org/10.1038/sj.bjc.6605578.

  • 51.

    Asif HM, Sultana S, Akhtar N, Rehman JU, Rehman RU. Prevalence, risk factors and disease knowledge of breast cancer in Pakistan. Asian Pac J Cancer Prev. 2014;15(11):4411-6. [PubMed ID: 24969861]. https://doi.org/10.7314/apjcp.2014.15.11.4411.

  • 52.

    Sadeghi S, Sardari S, Mohammamdi HR, Alemzadeh M. Incidence Trend of Primary Brain Tumors in Children and Adolescents in Iran: A Systematic Review and Meta-Analysis. Int J Pediatr. 2023;11(2):17428-37.

  • 53.

    Jazayeri SB, Shokraneh F, Ramezani R, Alimi M, Saadat S, Rahimi-Movaghar V. [Epidemiology of Primary Brain and Spinal Cord Tumors in Iran: a systematic review]. Neurosci J Shefaye Khatam. 2013;1(2):13-20. Persian. https://doi.org/10.18869/acadpub.shefa.1.2.13.

  • 54.

    Nakasu S, Notsu A, Nakasu Y. Prevalence of incidental meningiomas and gliomas on MRI: a meta-analysis and meta-regression analysis. Acta Neurochir (Wien). 2021;163(12):3401-15. [PubMed ID: 34227013]. https://doi.org/10.1007/s00701-021-04919-8.

  • 55.

    McKinney PA. Brain tumours: incidence, survival, and aetiology. J Neurol Neurosurg Psychiatry. 2004;75 Suppl 2(Suppl 2):ii12-7. [PubMed ID: 15146034]. [PubMed Central ID: PMC1765660]. https://doi.org/10.1136/jnnp.2004.040741.

  • 56.

    Jiang T, Tang GF, Lin Y, Peng XX, Zhang X, Zhai XW, et al. Prevalence estimates for primary brain tumors in China: a multi-center cross-sectional study. Chin Med J (Engl). 2011;124(17):2578-83. [PubMed ID: 22040406].

  • 57.

    Porter KR, McCarthy BJ, Freels S, Kim Y, Davis FG. Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro Oncol. 2010;12(6):520-7. [PubMed ID: 20511189]. [PubMed Central ID: PMC2940648]. https://doi.org/10.1093/neuonc/nop066.